Johnson & Johnson (NYSE:JNJ) Holdings reduced by TFC Financial Management


TFC Financial Management reduced its position in shares of Johnson & Johnson (NYSE:JNJGet a rating) by 1.3% in the first quarter, according to its latest filing with the Securities and Exchange Commission (SEC). The fund held 57,815 shares of the company after selling 732 shares during the period. Johnson & Johnson represents 2.9% of TFC Financial Management’s investment portfolio, making it its 5th largest position. TFC Financial Management’s holdings in Johnson & Johnson were worth $10,247,000 at the end of the most recent reporting period.

Other institutional investors have also recently changed their positions in the company. Riversedge Advisors LLC increased its stake in Johnson & Johnson by 8.6% in the fourth quarter. Riversedge Advisors LLC now owns 3,664 shares of the company worth $627,000 after buying 289 additional shares in the last quarter. Klingman & Associates LLC increased its stake in Johnson & Johnson by 1.2% in the 4th quarter. Klingman & Associates LLC now owns 13,045 shares of the company worth $2,232,000 after purchasing an additional 150 shares in the last quarter. DMG Group LLC purchased a new stake in Johnson & Johnson during the 4th quarter for a value of approximately $1,273,000. LeJeune Puetz Investment Counsel LLC increased its holding in Johnson & Johnson shares by 4.5% in the fourth quarter. LeJeune Puetz Investment Counsel LLC now owns 27,215 shares of the company valued at $4,656,000 after acquiring an additional 1,180 shares in the last quarter. Finally, Yousif Capital Management LLC purchased a new equity stake in Johnson & Johnson during Q4 valued at approximately $71,627,000. Hedge funds and other institutional investors own 68.78% of the company’s shares.

Johnson & Johnson Stock up 1.0%

Shares of Johnson & Johnson Stocks opened at $174.59 on Thursday. The company has a current ratio of 1.42, a quick ratio of 1.14 and a debt ratio of 0.37. The company’s fifty-day simple moving average is $175.57 and its two hundred-day simple moving average is $174.49. The company has a market capitalization of $459.42 billion, a P/E ratio of 25.41, a PEG ratio of 3.31 and a beta of 0.59. Johnson & Johnson has a 12-month low of $155.72 and a 12-month high of $186.69.

Johnson & Johnson (NYSE:JNJGet a rating) last released its results on Tuesday, July 19. The company reported earnings per share of $2.59 for the quarter, beating analyst consensus estimates of $2.57 by $0.02. The company posted revenue of $24.02 billion for the quarter, versus a consensus estimate of $23.85 billion. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.14%. The company’s revenue increased by 3.0% compared to the same quarter last year. During the same period of the previous year, the company achieved EPS of $2.48. Research analysts expect Johnson & Johnson to post EPS of 10.05 for the current year.

Johnson & Johnson announces dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 6. Shareholders of record on Tuesday, August 23 will receive a dividend of $1.13. This represents a dividend of $4.52 on an annualized basis and a dividend yield of 2.59%. The ex-date of this dividend is Monday, August 22. Johnson & Johnson’s dividend payout ratio is currently 65.79%.

Wall Street analysts predict growth

A number of brokerages have recently released reports on JNJ. Credit Suisse Group raised its price target on Johnson & Johnson from $200.00 to $205.00 and gave the company an “outperform” rating in a Wednesday (April 20) research report. Daiwa Capital Markets assumed coverage for Johnson & Johnson shares in a Wednesday, June 22 research note. They gave the company an “outperform” rating. Raymond James raised his price target on Johnson & Johnson shares from $195.00 to $196.00 and gave the stock an “outperform” rating in a Wednesday, April 20 research note. Citigroup lowered its price target on Johnson & Johnson shares from $205.00 to $201.00 in a Wednesday, July 20 report. Finally, Morgan Stanley raised its price target on Johnson & Johnson shares from $173.00 to $174.00 and gave the stock an “equal weight” rating in a Friday, July 8 report. Four analysts gave the stock a hold rating, five gave the company a buy rating and one gave the company’s stock a strong buy rating. According to MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $189.89.

Insider Trading at Johnson & Johnson

In related news, EVP Kathryn E. Wengel sold 40,000 shares in a trade dated Friday, June 10. The shares were sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the sale, the executive vice president now directly owns 71,311 shares of the company, valued at approximately $12,336,803. The sale was disclosed in a legal filing with the Securities & Exchange Commission, accessible via the SEC website. In other Johnson & Johnson news, CAO Robert J. Decker sold 8,462 shares of the company in a trade dated Thursday, May 26. The shares were sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the transaction, the chief accountant now owns 15,473 shares of the company, valued at approximately $2,785,140. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available via this hyperlink. Additionally, Executive Vice President Kathryn E. Wengel sold 40,000 shares of the company in a transaction dated Friday, June 10. The shares were sold at an average price of $173.00, for a total transaction of $6,920,000.00. As a result of the transaction, the executive vice president now owns 71,311 shares of the company, valued at approximately $12,336,803. Disclosure of this sale can be found here. Insiders own 0.35% of the shares of the company.

About Johnson & Johnson

(Get a rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures and sells various healthcare products worldwide. The Company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the brands AVEENO, CLEAN & CLEAR, DR.

Read more

Want to see what other hedge funds own JNJ? Visit HoldingsChannel.com for the latest 13F filings and insider trading for Johnson & Johnson (NYSE:JNJGet a rating).

Institutional ownership by quarter for Johnson & Johnson (NYSE: JNJ)



Get news and reviews for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily newsletter.